WAM
RCKT icon

Wolverine Asset Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Wolverine Asset Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-7,600
Closed -$172K – 1652
2019
Q4 		$172K Sell
7,600
-300
-4% -$5.01K ﹤0.01% 996
2019
Q3 		$92K Buy
+7,900
New +$98K ﹤0.01% 1109

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Wolverine Asset Management's RCKT Position: Q3 2023 in Review

Wolverine Asset Management sold out of Rocket Pharmaceuticals (RCKT) in Q3 2023, closing a stake of 399 shares — an estimated $7.93K sold.

Wolverine Asset Management first reported a position in RCKT in Q4 2022 and held it in 3 quarters. The position peaked at $7.93K in Q2 2023. 175 funds tracked by Wall St. Rank hold RCKT as of Q3 2023.

  • Wolverine Asset Management reported no remaining Rocket Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Wolverine Asset Management sold 399 Rocket Pharmaceuticals shares in Q3 2023, an estimated $7.93K.
  • Wolverine Asset Management first reported a position in Rocket Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • Wolverine Asset Management's Rocket Pharmaceuticals position peaked at $7.93K in Q2 2023.
  • 175 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2023.

Based on Wolverine Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.